0.76
+0.0218(+2.96%)
Currency In USD
| Previous Close | 0.74 |
| Open | 0.75 |
| Day High | 0.77 |
| Day Low | 0.7 |
| 52-Week High | 2.35 |
| 52-Week Low | 0.36 |
| Volume | 2.72M |
| Average Volume | 4.81M |
| Market Cap | 126.45M |
| PE | -1.01 |
| EPS | -0.75 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 0.95 |
| Change | 0.02 |
If you invested $1000 in Tenaya Therapeutics, Inc. (TNYA) since IPO date, it would be worth $49.45 as of January 14, 2026 at a share price of $0.759. Whereas If you bought $1000 worth of Tenaya Therapeutics, Inc. (TNYA) shares 3 years ago, it would be worth $301.19 as of January 14, 2026 at a share price of $0.759.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Si
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with SitesSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission